Ultragenyx Pharmaceutical... (RARE)
43.39
0.90 (2.12%)
At close: Feb 18, 2025, 3:59 PM
43.62
0.53%
After-hours: Feb 18, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 42.5 |
| Market Cap | 4.01B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.29 |
| PE Ratio (ttm) | -6.9 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 44.99 |
| Volume | 550,561 |
| Avg. Volume (20D) | 809,945 |
| Open | 43.05 |
| Previous Close | 42.49 |
| Day's Range | 42.57 - 44.70 |
| 52-Week Range | 37.02 - 60.37 |
| Beta | undefined |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 1,276
Stock Exchange NASDAQ
Ticker Symbol RARE
Website https://www.ultragenyx.com
Analyst Forecast
According to 14 analyst ratings, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 94.75% from the latest price.
Buy 92.86%
Hold 7.14%
Sell 0.00%
6 months ago
+14.31%
Ultragenyx Pharmaceuticals shares are trading high...
Unlock content with
Pro Subscription
6 months ago
-1.93%
Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.
